Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA-01: Palazestrant vs Standard of Care in ER+/HER2- Advanced Breast Cancer
NCT06016738Phase 3Active, not recruiting
- Sponsor
- Olema Oncology
- Start
- Nov 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of palazestrant in breast cancer, sponsored by Olema Oncology. Started Nov 2023; status: active, not recruiting.
02
Drugs
palazestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06016738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016738.